NewEdge Advisors’s AbCellera Biologics ABCL Stock Holding History

NewEdge Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$117K	Buy	14,852 +14,552	+4,851%	+$71.1K	﹤0.01%	2906
2026 Q1	$1.05K	Hold	300	–	–	﹤0.01%	3898
2025 Q4	$1.03K	Hold	300	–	–	﹤0.01%	3980
2025 Q3	$1.51K	Hold	300	–	–	﹤0.01%	3831
2025 Q2	$1.03K	Hold	300	–	–	﹤0.01%	3713
2025 Q1	$669	Hold	300	–	–	﹤0.01%	3674
2024 Q4	$879	Hold	300	–	–	﹤0.01%	3584
2024 Q3	$780	Sell	300 -300	-50%	-$831	﹤0.01%	3557
2024 Q2	$1.78K	Hold	600	–	–	﹤0.01%	3361
2024 Q1	$2.72K	Buy	600 +300	+100%	+$1.53K	﹤0.01%	3310
2023 Q4	$1.71K	Hold	300	–	–	﹤0.01%	3370
2023 Q3	$1.38K	Hold	300	–	–	﹤0.01%	3121
2023 Q2	$1.94K	Hold	300	–	–	﹤0.01%	3106
2023 Q1	$2.26K	Sell	300 -420	-58%	-$3.81K	﹤0.01%	3002
2022 Q4	$5.07K	Buy	+720	New	+$8.32K	﹤0.01%	2585

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

NewEdge Advisors's ABCL Position: Q2 2026 in Review

NewEdge Advisors increased its AbCellera Biologics (ABCL) stake by 4,851% in Q2 2026, buying an estimated $71.1K and bringing the position to 14,852 shares worth $117K. The position accounts for ﹤0.01% of the portfolio, ranked #2906.

NewEdge Advisors first reported a position in ABCL in Q4 2022 and has held it in 15 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

NewEdge Advisors held 14,852 shares of AbCellera Biologics worth $117K as of Q2 2026.
NewEdge Advisors bought 14,552 AbCellera Biologics shares in Q2 2026, an estimated $71.1K.
AbCellera Biologics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2906 holding.
NewEdge Advisors first reported a position in AbCellera Biologics in Q4 2022 and has held it in 15 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.